Filtered By:
Cancer: Colorectal Cancer
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 1289 results found since Jan 2013.
Expression of sphingosine-1-phosphate receptor 2 is correlated with migration and invasion of human colon cancer cells: A preliminary clinical study
Oncol Lett. 2022 Jun 1;24(1):241. doi: 10.3892/ol.2022.13361. eCollection 2022 Jul.ABSTRACTSphingosine-1-phosphate (S1P) is a bioactive phospholipid that serves as a potent mediator of cell proliferation, differentiation and apoptosis by binding to S1P receptors (S1PRs). S1P signalling is involved in the pathogenesis of numerous types of disease, including cancer. To the best of our knowledge, however, little is known about the expression patterns of S1PRs and their role in human colorectal cancer (CRC) cell migration and invasion. The aim of the present study was to investigate the role of S1P signalling in the metastasis...
Source: Oncology Letters - June 20, 2022 Category: Cancer & Oncology Authors: Junjun Yan Yi Chen Qibiao Wu Le Shao Xiqiao Zhou Source Type: research
GSE148795 Study of transcriptional effects of FOXS1 silencing and TGF-beta treatment in SNU-449 hepatocellular carcinoma cell line
Conclusions: FOXS1 is a novel TGFβ target and a key mediator of EMT. Its induction in cancer is associated with a poor prognosis. Thus, determining the exp ression of FOXS1 in advanced tumors in which the pro-metastatic arm of TGFβ is activated could help to identify patients who may benefit from targeted therapies using TGFβ inhibitors.
Source: GEO: Gene Expression Omnibus - June 15, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
MiR-132-3p inhibits proliferation, invasion and migration of colorectal cancer cells via down-regulating FOXP2 expression
CONCLUSIONS: miR-132-3p inhibits the proliferation, migration and invasion of CRC cells. This is likely achieved via negative regulation of the targeted FOXP2 expression. This role may be further explored for therapeutic applications in CRC.PMID:35667086 | DOI:10.18388/abp.2020_5813
Source: Cancer Control - June 6, 2022 Category: Cancer & Oncology Authors: Rui Huang Guoan Xiang Xiaopeng Duan Hanning Wang Ke He Jinfeng Xiao Source Type: research
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
CONCLUSIONS: Our study shows that CRC resistance to EGFR inhibitors results primarily from the inability of the inhibitors to downregulate their target and that a PEPDG278D-based combination treatment overcomes the resistance.PMID:35650607 | DOI:10.1186/s13046-022-02389-z
Source: Cell Research - June 1, 2022 Category: Cytology Authors: Lu Yang Arup Bhattacharya Yun Li Sandra Sexton Xiang Ling Fengzhi Li Yuesheng Zhang Source Type: research
FJX1 as a candidate diagnostic and prognostic serum biomarker for colorectal cancer
CONCLUSION: Our findings provided a novel strategy to identify diagnostic biomarkers based on public datasets, and suggested that FJX1 was a candidate diagnostic and prognostic biomarker in CRC patients.PMID:35650386 | DOI:10.1007/s12094-022-02852-5
Source: Clinical Colorectal Cancer - June 1, 2022 Category: Cancer & Oncology Authors: Lei Liu Yecai Huang Yan Li Qiong Wang Yaying Hao L üye Liu Xue Yao Xiuju Yao Yi Wei Xiaobin Sun Yuanbiao Guo Source Type: research
